Yıl: 2020 Cilt: 29 Sayı: 4 Sayfa Aralığı: 289 - 296 Metin Dili: İngilizce DOI: 10.5152/turkjnephrol.2020.4221 İndeks Tarihi: 05-05-2021

Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease

Öz:
Objective: Secondary renal AA amyloidosis (RAAA) presents with proteinuria and/or as nephrotic syndrome and progress-es to end stage renal disease (ESRD) insidiously. However, some patients with secondary amyloidosis show a more rapid renal disease progression than the usual course. In this study, we aimed to investigate the underlying cause of the rapidly progressive renal disease in the patients with secondary amyloidosis.Materials and Methods: Patients with kidney biopsy proven secondary RAAA were divided into 2 groups: the rapidly pro-gressive group (estimated glomerular filtration rate >60 mL/min, who needed renal replacement therapy within one year of diagnosis) and the control group. Biopsy specimens were reevaluated for glomerular-vascular amyloid load, tubular atrophy, interstitial fibrosis, and interstitial inflammation. The biopsy characteristics and biochemical parameters were compared between the groups. Results: Histopathological examination showed global amyloid deposition, vascular pole involvement, peritubular capil-lary amyloid deposition, and severe interstitial inflammation associated with rapidly progressive disease. Estimated glo-merular filtration rate was lower and proteinuria was higher in the rapidly progressive group than in the control group. Vascular pole amyloid deposition was found to be a predictor of ESRD in multivariate analysis. Conclusion: This study shows that higher amyloid deposition and severe inflammation revealed in in kidney biopsy of secondary RAAA cases can be risk factors for rapidly progressive renal failure.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Süleymanlar G, Ateş K, Seyahi N. Türkiye'de Nefroloji, Diyaliz ve Transplantasyon. Ankara: Türk Nefroloji Derneği Yayınları; 2018.
  • 2. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-71. [Crossref]
  • 3. Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine (Baltimore) 2017; 96: e7859. [Crossref]
  • 4. Tang W, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, et al. End-stage renal failure due to amyloidosis: Outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant 2013; 28: 455-61. [Crossref]
  • 5. Watanabe T, Saniter T. Morphological and clinical features of renal amyloidosis. Virchows Arch A Pathol Anat Histol 1975; 366: 125-35. [Crossref]
  • 6. Kendi Celebi Z, Kiremitci S, Ozturk B, Akturk S, Erdogmus S, Duman N, et al. Kidney biopsy in AA amyloidosis: Impact of histopathology on prognosis. Amyloid 2017; 24: 176-82. [Crossref]
  • 7. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37: 1804-11. [Crossref]
  • 8. Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, et al. Long-term prognosis of AL and AA renal amyloidosis: A Japanese single-center experience. Clin Exp Nephrol 2017; 21: 212-27. [Crossref]
  • 9. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, et al. Renal involvement in systemic amyloidosis. Nephrol Dial Transplant 2008; 23: 941-51. [Crossref]
  • 10. Yamanouchi M, Furuichi K, Hoshino J, Toyama T, Hara A, Shimizu M, et al. Nonproteinuric versus proteinuricphenotypesindiabetic kidney disease: A propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care 2019; 42: 891-902. [Crossref]
  • 11. Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, et al. Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid 2017; 24: 136-7. [Crossref]
  • 12. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-9. [Crossref]
  • 13. Khalighi MA, Wallace WD, Palma-Diaz MF. Amyloid nephropathy. Clin Kidney J 2014; 7: 97-106. [Crossref]
  • 14. Thongprayoon C, Satirapoj B, Kaewput C, Bathini T, Mao MA, Cato LD, et al. Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study. Ther Apher Dial. 2020 Jan 30. doi: 10.1111/1744-9987.13480. [Epub Ahead of Print]. [Crossref]
  • 15. Reichel H, Zee J, Tu C, Young E, Pisoni RL, Duttlinger J, et al. Chronic kidney disease progression and mortality risk profiles in Germany: Results from the Chronic Kidney Disease Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2020; 35: 803-810. [Crossref]
  • 16. Verine J, Mourad N, Desseaux K, Vanhille P, Noël LH, Beaufils H, et al. Clinical and histological characteristics of renal AA amyloidosis: A retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007; 38: 1798-809. [Crossref]
  • 17. Kutlugün AA, Altun B, Aktan U, Turkmen E, Altindal M, Yildirim T, et al. The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients. Amyloid 2012; 19: 28-32. [Crossref]
  • 18. Navar LG. Intrarenal renin-angiotensin system in regulation of glomerular function. Curr Opin Nephrol Hypertens 2014; 23: 38-45. [Crossref]
  • 19. Ueno T, Takeda K, Nagata M. Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant 2012; 27: 633-9. [Crossref]
  • 20. Lee YH, Kim EY, Jeong DW, Kim YG, Lee SH, Song R, et al. Complete remission of nephrotic syndrome without resolution of amyloid deposit after anti-tumor necrosis factor α therapy in a patient with ankylosing spondylitis. J Clin Rheumatol 2016; 22: 86-8. [Crossref]
  • 21. Paueksakon P. Amyloid nephropathy: A practical diagnostic approach and review on pathogenesis [Internet]. IntechOpen. 2016 Aug 24. Available from: https://www.intechopen.com/books/exploring-new-findings-on-amyloidosis/amyloid-nephropathy-a-practical-diagnostic-approach-and-review-on-pathogenesis [Crossref]
  • 22. Yamagata A, Uchida T, Yamada Y, Nakanishi T, Nagai K, Imakiire T, et al. Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: A case report. BMC Nephrol 2017; 18: 10-3. [Crossref]
APA Kendi Celebi Z, Kiremitci S, Eren Sadioğlu R, keven k (2020). Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. , 289 - 296. 10.5152/turkjnephrol.2020.4221
Chicago Kendi Celebi Zeynep,Kiremitci Saba,Eren Sadioğlu Rezzan,keven kenan Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. (2020): 289 - 296. 10.5152/turkjnephrol.2020.4221
MLA Kendi Celebi Zeynep,Kiremitci Saba,Eren Sadioğlu Rezzan,keven kenan Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. , 2020, ss.289 - 296. 10.5152/turkjnephrol.2020.4221
AMA Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. . 2020; 289 - 296. 10.5152/turkjnephrol.2020.4221
Vancouver Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. . 2020; 289 - 296. 10.5152/turkjnephrol.2020.4221
IEEE Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k "Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease." , ss.289 - 296, 2020. 10.5152/turkjnephrol.2020.4221
ISNAD Kendi Celebi, Zeynep vd. "Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease". (2020), 289-296. https://doi.org/10.5152/turkjnephrol.2020.4221
APA Kendi Celebi Z, Kiremitci S, Eren Sadioğlu R, keven k (2020). Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turkish journal of nephrology (Online), 29(4), 289 - 296. 10.5152/turkjnephrol.2020.4221
Chicago Kendi Celebi Zeynep,Kiremitci Saba,Eren Sadioğlu Rezzan,keven kenan Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turkish journal of nephrology (Online) 29, no.4 (2020): 289 - 296. 10.5152/turkjnephrol.2020.4221
MLA Kendi Celebi Zeynep,Kiremitci Saba,Eren Sadioğlu Rezzan,keven kenan Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turkish journal of nephrology (Online), vol.29, no.4, 2020, ss.289 - 296. 10.5152/turkjnephrol.2020.4221
AMA Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turkish journal of nephrology (Online). 2020; 29(4): 289 - 296. 10.5152/turkjnephrol.2020.4221
Vancouver Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turkish journal of nephrology (Online). 2020; 29(4): 289 - 296. 10.5152/turkjnephrol.2020.4221
IEEE Kendi Celebi Z,Kiremitci S,Eren Sadioğlu R,keven k "Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease." Turkish journal of nephrology (Online), 29, ss.289 - 296, 2020. 10.5152/turkjnephrol.2020.4221
ISNAD Kendi Celebi, Zeynep vd. "Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease". Turkish journal of nephrology (Online) 29/4 (2020), 289-296. https://doi.org/10.5152/turkjnephrol.2020.4221